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Caspase-2 deficiency enhances whole-body
carbohydrate utilisation and prevents high-fat
diet-induced obesity
Claire H Wilson1, Andrej Nikolic1, Stephen J Kentish2,3, Marianne Keller2,3, George Hatzinikolas2, Loretta Dorstyn1, Amanda J Page2,3,4
and Sharad Kumar*,1,4
Caspase-2 has been shown to be involved in metabolic homeostasis. Here, we show that caspase-2 deficiency alters basal energy
metabolism by shifting the balance in fuel choice from fatty acid to carbohydrate usage. At 4 weeks of age, whole-body
carbohydrate utilisation was increased in Casp2−/− mice and was maintained into adulthood. By 17 weeks of age, Casp2−/− mice
had reduced white adipose mass, smaller white adipocytes decreased fasting blood glucose and plasma triglycerides but
maintained normal insulin levels. When placed on a 12-week high-fat diet (HFD), Casp2−/− mice resisted the development of
obesity, fatty liver, hyperinsulinemia and insulin resistance. In addition, HFD-fed Casp2−/− mice had reduced white adipocyte
hypertrophy, apoptosis and expansion of both subcutaneous and visceral adipose depots. Increased expression of UCP1 and the
maintenance of adiponectin levels in white adipose tissue of HFD-fed Casp2−/− mice indicated increased browning and adipocyte
hyperplasia. We found that while the preference for whole-body carbohydrate utilisation was maintained, HFD-fed Casp2−/− mice
were not impaired in their ability to switch to utilising fats as a fuel source. Our findings suggest that caspase-2 impacts basal
energy metabolism by regulating adipocyte biology and fat expansion, most likely via a non-apoptotic function. Furthermore, we
show that caspase-2 deficiency shifts the balance in fuel choice towards increased carbohydrate utilisation and propose that this
is due to mild energy stress. As a consequence, Casp2−/−mice show an adaptive remodelling of adipose tissue that protects from
HFD-induced obesity and improves glucose homeostasis while paradoxically increasing their susceptibility to oxidative stress
induced damage and premature ageing.
Cell Death and Disease (2017) 8, e3136; doi:10.1038/cddis.2017.518; published online 26 October 2017
Whole-body energy homeostasis is vital for healthy ageing
and survival1,2 with its perturbation contributing to the
development of numerous disease including obesity, type II
diabetes and cancer.1–4 In response to changes in energy
supply and demand, fuel choice (fat versus carbohydrate),
conversion, utilisation and storage fluctuate to maintain
energy homeostasis.1,5 This involves multiple levels of
complex regulation and cross-talk between different organs,
tissues and cell types.1 Such fluctuations in fuel choice also
occur with differing cell states and as an adaptive response to
stress conditions.5 As a consequence, these fluctuations can
alter fuel choice in distant organs through systemic commu-
nication, causing shifts in whole-body energy metabolism.5
The molecular components that control changes and decision
for fuel choice is unclear and key to understanding the
regulation of energy homeostasis and how its perturbation
contributes to diseases such as obesity.
Caspase-2, is the most evolutionary conserved member of
the mammalian caspase (cysteine-dependent aspartate
specific proteases) family, and is an important regulator of
metabolism, ageing and tumour suppression (reviewed in
Miles et al.6 and Puccini et al.7). Previously, we identified
caspase-2 as a potential regulator of lipid metabolism and
glucose homeostasis.8,9 In mice, caspase-2 deficiency
(Casp2−/−) results in several signs of premature ageing-
related traits10,11 and increased susceptibility to oxidative
stress-induced damage and induced tumour formation.12–15
Intriguingly caspase-2 deficiency protects from aged-induced
glucose intolerance independent of insulin sensitivity.8,9 Aged
Casp2−/− mice also have altered body composition (reduced
fat and muscle mass),11 smaller white adipocytes, enhanced
fasting-induced lipolysis of white adipose tissue (WAT) and
increased fasting-induced autophagy of skeletal muscle and
liver.8 In other studies, Casp2−/− mice were found to be
protected from Western diet (45% kJ from fat, water
supplemented fructose and glucose) induced obesity, insulin
resistance and non-alcoholic fatty liver disease (NAFLD)16
and caspase-2 has been linked with the apoptotic progression
of NAFLD to more severe non-alcoholic hepatosteatosis.17,18
Caspase-2 deficiency has also been shown to protect from
streptozotocin type I diabetes induced bone marrow
adiposity.19 These data indicate that caspase-2 may have a
direct role in adipocyte biology. However, the precise
mechanism of caspase-2 function remains unknown and
how its deficiency contributes to improved metabolic out-
comes while promoting ageing is yet to be determined.
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In this study, we carried out metabolic monitoring with
indirect calorimetry and high-fat diet (HFD) feeding (60% kJ
from fat) to further investigate the in vivo role of caspase-2 in
metabolism.We show that caspase-2 deficiency protects from
the development of HFD-induced obesity, NAFLD and insulin
resistance. Our data indicate that caspase-2 is an important
regulator of glucose homeostasis and basal energy metabo-
lism and supports a role for caspase-2 inmodulating adipocyte
biology and fat expansion.
Results
Caspase-2 deficiency shifts whole-body fuel utilisation
towards increased carbohydrate oxidation. To further
investigate the role of caspase-2 in metabolism, we assessed
the metabolic phenotype of young Casp2−/−mice. At 4 weeks
of age (1-week post-weaning) Casp2−/− mice and wild-type
(WT) controls fed a standard laboratory diet (SLD; 18% kJ
from fat) displayed similar body weight, food intake, move-
ment, energy expenditure and feeding behaviour (Figure 1a,
Supplementary Figure S1). Indirect calorimetry revealed a
significant increase in VCO2 production (Figure 1c) in
Casp2−/− mice but VO2 consumption was comparable to
WT mice (Figure 1b). Respiratory quotient (RQ), which
represents the utilisation of carbohydrate or fat as fuel, was
significantly higher in Casp2−/− mice (Figure 1d). This
indicates that caspase-2 deficiency results in a shift in
whole-body fuel utilisation towards increased carbohydrate
oxidation.
Caspase-2 deficiency protects from HFD-induced obe-
sity, hyperlipidaemia, fatty liver and insulin resistance.
At 5 weeks of age, mice were either placed on a HFD (60%
kJ from fat), or maintained on SLD for 12 weeks. In both
dietary groups, Casp2−/− mice gained significantly less body
weight compared with WT controls and had significantly
decreased mass of gonadal adipose tissue (gWAT)
(Figures 2a and b). HFD-fed Casp2−/− mice also showed
reduced mass of interscapular brown adipose tissue (iBAT)
and liver compared with HFD-fed WT controls (Figure 2b).
Magnetic resonance imaging (MRI) revealed a significant
reduction in total body fat content of HFD-fed Casp2−/− mice
with decreased subcutaneous adipose tissue (SAT) and
visceral adipose tissue (VAT) depots (Figure 2d). In both
dietary groups, plasma triglycerides were significantly
reduced in Casp2−/− mice, whereas HFD-fed WT mice
developed hypertriglyceridemia (Figure 2c). Levels of plasma
cholesterol were not different (data not shown). SLD-fed
Casp2−/− mice had smaller sized adipocytes in gWAT that
were maintained following HFD feeding along with decreased
lipid accumulation iBAT (Figures 2f and g). Consistent with
differences in fat mass, Casp2−/− mice had significantly
reduced levels of plasma leptin and leptin gene expression in
gWAT in both dietary groups and maintained normal
adiponectin gene expression following HFD feeding
(Figure 2e), consistent with previous findings in aged
SLD-fed Casp2−/−mice.8
Differences in liver mass between HFD-fed mice were
attributable to altered lipid accumulation. Macroscopically,
Casp2−/− mice were protected from HFD-induced NAFLD,
whereas 10/16 HFD-fed WT mice had clear signs of
hepatosteatosis (enlarged, white mottled liver), which was
confirmed by histological analysis (Figure 2h). Analysis of liver
gene expression using a fatty liver-specific quantitative PCR
(qPCR) array revealed a small number (10/84) of significant
differences between HFD-fed WT and Casp2−/− mice
(Figure 3a and Supplementary Data S1). These were mainly
due to HFD-induced changes in WT but not Casp2−/−mice as
demonstrated by differences in the expression of the fatty acid
transporter gene CD36 (confirmed by individual qPCR)
(Figure 3b). Importantly, no differences were observed in
expression of any genes between SLD-fed WTand Casp2−/−
mice, including those involved in cholesterol and
lipid metabolism/transport (Figure 3a and Supplementary
Data S1).
Following 8 weeks of HFD feeding (13 weeks of age) glucose
tolerance and insulin sensitivity were significantly improved in
Casp2−/− mice compared with WT controls as measured by
intraperitoneal glucose tolerance testing (IPGTT) and insulin
tolerance testing (IPITT) (Figures 2i and j). After 12 weeks
(17 weeks of age), fasting blood glucose was significantly lower
in both SLD- and HFD-fed Casp2−/− mice (Figure 2k). This
appeared to be independent of insulin as fasting plasma insulin
levels did not differ between SLD-fed WT and Casp2−/− mice
(Figure 2k). In addition, Casp2−/− mice did not develop HFD-
induced hyperinsulinemia or insulin resistance as measured by
the homeostasis model assessment of insulin resistance
(HOMA-IR) value (Figure 2k).
Combined, these findings indicate that caspase-2 is
involved in the maintenance of adipocyte size, function and
glucose homeostasis and importantly that caspase-2 defi-
ciency can improve adipose function and protects from HFD-
induced obesity, NAFLD and fatty liver. Furthermore, the data
indicate that the phenotype of HFD-fed Casp2−/− mice is not
the result of impaired lipid storage, rather there is a change in
utilisation and/or metabolism of lipids in adipocytes.
Shifts in whole-body fuel utilisation are maintained in
HFD-fed Casp2−/− mice. After 8 weeks of HFD feeding
(13 weeks of age), metabolic phenotyping was repeated.
SLD-fed mice maintained the same metabolic phenotype as
observed at 4 weeks of age (Figure 4 and Supplementary
Figure S2). Food intake and feeding behaviour remained
similar between genotypes on HFD (Figure 4a and
Supplementary Figure S2) and this was despite differences
in leptin levels (Figure 2e). Interestingly, HFD-fed
Casp2−/− mice had a small but significant increase in total
daily energy expenditure corresponding with a similar
increase in total daily movement (Figure 4a and
Supplementary Figure S2). Fat oxidation requires increased
oxygen consumption and HFD feeding is known to shift the
balance in fuel choice towards increased fat utilisation.20
Consistent with this, in both genotypes, HFD feeding
significantly increased total VO2 and decreased the RQ
value (Figures 4b and d). However, HFD-fed Casp2−/− mice
maintained significantly higher levels of VCO2 and the RQ
value when compared with HFD-fed WT controls (Figures 4c
and d). Importantly, the magnitude of change in RQ value
upon HFD feeding was similar in both genotypes. These data
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Figure 1 Caspase-2 deficiency shifts whole-body fuel utilisation in SLD-fed mice. Metabolic monitoring with indirect calorimetry performed on 4-week old WTand Casp2−/−
mice after 1 week of ad libitum SLD-feeding. (a) Body weight, total daily food intake, activity (movement) and energy expenditure (EE). (b) VO2 consumption (c) VCO2 carbon-
dioxide production and (d) RQ determined over 24- h period with 12-h light–dark cycles. Values are means± S.D. (bar graphs) and means±S.E.M (scatter plots) (n= 22–23 per
group). Statistical significance indicated as *Po0.05, **Po0.01, ***Po0.001
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indicate that while Casp2−/− mice maintain their preference
for utilising carbohydrates as a fuel source they are not
impaired in their ability to switch to utilising fats.
Altered liver and skeletal muscle metabolism do not
affect fuel choice in Casp2−/− mice. Previously, we found
activity of the mitochondrial oxidative phosphorylation
(OXPHOS) complex III to be reduced in livers of Casp2−/−
mice.9 As inhibition of OXPHOS is known to result in
increased glycolysis, this could account for the observed
adaptive shift towards increased glycolytic (carbohydrate)
fuel use in Casp2−/−mice.21 However, there was no sig-
nificant difference in gene expression of key enzymes
involved in glycolysis and fatty acid oxidation in livers of
Casp2−/− mice consistent with our previous findings.8
According to the Randle cycle, on the basis of substrate
availability, increased fatty acid oxidation reduces glucose
utilisation;22 conversely, impaired and reduced fatty acid
oxidation can lead to increases in glucose utilisation.
Increases in whole-body carbohydrate utilisation and protec-
tion from obesity can also been result from impaired
mitochondrial fatty acid oxidation in skeletal muscle.23
Therefore, we carried out a gene expression screen
of skeletal muscle (quadriceps) using a qPCR array specific
for glucose/glycogen metabolism genes and found minimal
differences between genotypes on both diets (Figure 5a and
Supplementary Data S2). In addition, expression of key
genes involved in fatty acid transport and oxidation did not
differ between SLD-fed mice (Figure 5d). However, in
Casp2−/−mice, HFD feeding significantly increased expres-
sion of mitochondria fatty acid transporter Cpt1b and the
mitochondria uncoupling protein UCP3 compared with SLD
controls, as well as reduced levels of free fatty acids (FFAs) in
skeletal muscle, but not liver (Figures 5b-d). In HFD-fed
Casp2−/− mice, glycogen levels were lower in both skeletal
muscle and liver compared with WT controls but no
differences were observed between SLD-fed mice
(Figures 5b and c). These data indicate that altered
mitochondrial function and/or metabolism in the liver
and skeletal muscle of Casp2−/−mice are unlikely to have a
major contributing role to the shift in whole-body fuel
utilisation. In addition, this suggests that the tissue-specific
responses to metabolism in HFD feeding may differ in
Casp2−/− mice.
Casp2−/− mice do not show changes in gene expression
associated with insulin resistance in gWAT. As adipocyte
cell size positively correlates with glucose intolerance and
hyperinsulinaemia in obesity,24 we screened gWAT gene
expression against a panel of genes involved in insulin
resistance. HFD feeding altered the expression of a large
number of genes in WT but not Casp2−/− mice, which
Figure 2 Caspase-2 deficiency protects from HFD-induced obesity and results in metabolic improvements. WTand Casp2−/−mice were fed HFD for 12 weeks and blood and
tissue collected following a 6-h fast. (a) Body weight and weight gain over 12-week period (n= 11–15 per group). (b) Weight of gWAT, iBAT and liver (n= 14–16). (c) Fasting
plasma triglycerides (n= 11–14 per group). (d) MRI of HFD-fed mice after 12 weeks and calculated volumes of SATand VAT (n= 3 per group). (e and f) Adipokines assessed by
measurement of (e) plasma leptin (n= 8–10), and mRNA expression in gWAT (n= 5–6). (f–h) representative images of H&E staining of (f) gWAT, (g) iBAT and (h) liver, scale
bar= 50 μm. (i) IPGTTand (j) IPTTwas performed on WTand Casp2−/− mice (n= 7–8 per group) at 13 weeks of age after 8 weeks on HFD. (k) Fasting blood glucose (n= 14–
16 per group), plasma insulin (n= 8–10 per group) and calculated homeostatic model assessment of insulin resistance (HOMA-IR) (n= 8–10 per group) measured after
12 weeks on HFD. Mice were used at 16–17 weeks (including 12 weeks HFD feeding) unless otherwise stated. Values are means± S.D. (bar graphs) or means±S.E.M (scatter
plots). Statistical significance indicated as *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001
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Figure 3 Gene expression analysis of liver tissue from SLD- and HFD-fed WTand Casp2−/− mice. Expression of genes known to be involved in fatty liver identified as being
significantly altered (fold change relative to SLD-fed WT mice41.2 and Po0.05) by diet or genotype as measured by (a) 84-gene panel Mouse Fatty Liver qPCR array or (b)
single qPCR (n= 5–6 per group). (a) Values are average fold change of significant differences (t-test, n= 4–5 per group, Po0.05) between diet within each genotype (diet effect)
and between genotype within each dietary group (genotype effect) with green highlighting downregulation, red highlighting upregulation and grey highlighting indicating no
significant difference. (b) Values are means± S.D. (bar graphs). Statistical significance indicated as *Po0.05
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Figure 4 Increased carbohydrate utilisation is maintained in Casp2−/− mice fed SLD or HFD. Metabolic monitoring with indirect calorimetry was performed on 13-week old
WT and Casp2−/− mice after 8 weeks of ad libitum SLD- or HFD- feeding. (a) Body weight, total daily food intake, activity (movement) and energy expenditure (EE). (b) VO2
consumption (c) VCO2 production and (d) RQ determined over 24-h period with 12-h light–dark cycles. Values are means±S.D. (bar graphs) and means± S.E.M (scatter plots)
(n= 10–12 per group). Pair-wise comparisons were made between diet within each genotype (diet effect) and between genotype within each dietary group (genotype effect).
Statistical significance indicated as *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001 and #Po0.05 indicates effect of diet was different between genotypes as assessed by
two-way ANOVA
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resulted in a large number of significant differences between
genotypes on HFD (Figure 6a and Supplementary Data S3).
In WT mice, HFD decreased expression of 41/84 genes,
many involved in glucose uptake, lipid metabolism insulin
signalling and increased expression of 6/84 genes, whereas
in Casp2−/− mice, HFD altered expression of only 13/84
genes analysed (Figure 6a). The only significant difference
observed between SLD-fed mice was an increase in
expression of Nampt and Pdk2 in Casp2−/− mice compared
with WT controls (Figure 6a).
In obesity, adipogenesis can be impaired by dysregulation
of adipogenic genes.25 Indeed, several adipogenic genes,
including PPARγ and FABP4, were decreased in HFD-fed WT
but not Casp2−/− mice (Figure 6a). These differences were
confirmed by qPCR analysis as were differences in Glut4 and
PPARα expression (Figure 6b). Among the upregulated genes
in HFD-fed WT mice were markers of infiltrating macrophages
Cxcr4, Adgre1 and Ccr5 (Figure 6a).
Casp2−/− mice have reduced HFD-induced white adipo-
cyte cell death. In obesity, inflammatory infiltration occurs in
response to increases in apoptotic cell death of adipocytes,
and is a key driver in the pathogenesis of obesity.26
Assessment of apoptosis by TUNEL revealed almost a two-
fold increase in the number of TUNEL-positive dying white
adipocytes in gWAT of HFD-fed WT mice compared with
SLD-fed WT controls and HFD-fed Casp2−/− mice
(Figure 6c). Importantly, there was no difference in adipocyte
cell death between SLD-fed WTand Casp2−/−mice indicating
the likely importance of a non-apoptotic role of caspase-2 in
adipocyte biology.
Brown adipocyte cell death also contributes to the patho-
genesis of obesity by decreasing thermogenic activity of BAT;
however, no differences were observed between genotype or
diets (Supplementary Figure 3a). Immunoblot analysis
revealed an apparent decrease in pro-caspase-3 in gWAT
and iBAT of HFD-fed WT mice but no difference in cleaved
caspase-3 was detected (Figure 6d and Supplementary
Figure 3b). Caspase-2 has been linked to lipoapoptosis27
and has been suggested to be involved in cell death of
adipocytes following Western diet feeding.16 However, we
observed no difference in protein levels of full-length caspase-
2 or detection of its cleavage products in gWAT and iBAT of
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Phkb 1.20
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Fatty acid uptake and oxidation
Figure 5 Gene expression analysis of skeletal muscle tissue from SLD- and HFD-fed WT and Casp2−/− mice. (a) Expression of genes involved in glucose/glycogen
metabolism identified as being significantly altered by diet or genotype as measured by an 84-gene panel Glucose Metabolism qPCR array. Values are average fold change of
significant differences (t-test, n= 3–4 per group, Po0.05) between diet within each genotype (diet effect) and between genotype within each dietary group (genotype effect) with
green highlighting downregulation, red highlighting upregulation and grey highlighting indicating no significant difference. Glycogen and FFA levels were measured in (b) skeletal
muscle (quadriceps; n= 6 per group) and (c) liver (n= 6 per group) from WTand Casp2−/− mice fed SLD or HFD for 12 weeks. (d) qPCR used to measure expression of genes
involved in fatty acid uptake and oxidation (n= 5–6 per group). Values are means± S.D. Statistical significance indicated as *Po0.05, **Po0.01, ***Po0.001
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Caspase-2 deficiency increases HFD-induced browning
of gWAT. Adaptive thermogenesis in response to HFD
feeding can occur as a means to try and mitigate the effects
of increased lipid accumulation. To assess if this was altered
by caspase-2, gene expression analysis was used to
investigate differences in BAT thermogenesis and HFD-
induced browning of WAT (e.g. recruitment/development of
beige/brite cells). In iBAT, no differences were observed in the
expression of thermogenic genes (such as Cidea and
PGC-1α). Apart from significantly higher levels of Pepck1,
there were also no differences in expression of genes
involved in glucose and fatty acid transport/metabolism in
SLD-fed Casp2−/− mice (Figure 7a). Interestingly, levels of
uncoupling protein 1 (UCP1), a marker of BAT/thermogen-
esis, were significantly lower in iBAT of HFD-fed Casp2−/−
mice compared with WT controls (Figure 7a) but UCP1
protein levels did not notably differ between genotype or diet
(Figure 7c). In Casp2−/−mice, HFD feeding led to significantly
increased expression of Cpt1a relative to SLD-fed mice,





































Gene WT SLD HFD Pathway
Lep 4.17 -5.86 Adipokine signalling
Olr1 3.17 -3.64 Metabolite transport
Cxcr4 2.34 -2.34
Adgre1 2.30 -2.31 Infilitrating leukocyte marker (macrophage)
Ccr5 2.30 -2.06
Pycard 1.43 -1.58 -1.97 Inflammation; Innate immunity; apoptosis
Jak2 -1.62 Apoptosis










Nfkbia -1.55 1.51 Apoptosis; Adipokine signaling
Cs -1.50
Carbohydrate metabolism




Cd3e -2.83 -3.03 Infiltrating leukocyte marker
Lta4h -1.43
Tnfrsf1a -1.39 1.53






Pik3r1 -2.97 -1.96 1.87
Mapk3 -1.48
Mtor -1.45 1.52
Mapk9 -2.25 -1.31 1.99
Irs2 -2.50 2.24
Irs1 -4.13 3.88
Pik3ca -1.91 -1.46 1.50
Slc2a4 -2.49 2.66
Acacb -2.81 5.47


































































































Figure 6 Expression analysis of insulin resistance genes in gWATand adipocyte apoptosis in HFD-fed Casp2−/− mice. Expression of genes known to be involved in insulin
resistance identified as being significantly altered (fold change relative to SLD-fed WT mice41.2 and Po0.05) in gonadal WAT (gWAT) by diet or genotype as measured by (a)
an 84-gene panel Insulin Resistance qPCR array and verified by (b) individual qPCR analysis (n= 5–6 per group). (a) Values are average fold change of significant differences (t-
test, n= 4–5 samples per group, Po0.05) between diet within each genotype (diet effect) and between genotype within each dietary group (genotype effect) with green
highlighting downregulation, red highlighting upregulation and grey highlighting indicating no significant difference. (c) Representative images of TUNEL-positive cells in gWAT
after 12 weeks of SLD- or HFD feeding. Bar graph displays % of TUNEL-positive cells per field of view. (n= 3–5 per group). (d) Immunoblot analysis of total caspase-3 (Casp3)
and cleaved Casp3 in iBAT tissue with β-actin as loading control. Values are means±S.D. Statistical significance indicated as *Po0.05, **Po0.01, ****Po0.0001
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UCP2, Pepck1, PPARα and FGF21 was observed
(Figure 7a). In HFD-fed Casp2−/− mice, the expression of
Cpt1a, UCP2, UCP3, Pepck1 and ACOX was significantly
higher than observed in HFD-fed WT mice, whereas PPARα
and FGF21 were significantly lower (Figure 7a). This
suggests that iBAT activity is not altered by caspase-2
deficiency and does not contribute to the shift in fuel choice
or protection from obesity.
In gWAT, levels of UCP1 were significantly higher in HFD-
fed Casp2−/− mice indicating a potential increase in browning
(Figure 7b); however, UCP1 protein was not detectable by
immunoblotting (data not shown). Levels of UCP3 were also
significantly higher in HFD-fed Casp2−/−mice, whereas levels
of UCP2 were significantly lower (Figure 7c). Additional
markers of browning, including Cidea and β3-AR were not
detectable in gWAT and there was no difference in Dio2
expression (Figure 7b). In contrast to iBAT, HFD feeding did
not alter levels ofCpt1a in gWATofCasp2−/−mice (Figure 7b).
Adipose tissue p53 has been shown to have important roles
in insulin resistance and thermogenesis.28,29 As caspase-2
has also been linked with altered p53 response in several
studies,11,30–32 we investigated p53 expression in our sam-
ples. In both dietary groups, we observed increased levels of
p53 protein in iBAT and gWAT of Casp2−/− mice (Figures 7c
and d) and a decrease in adipose p53 protein upon HFD
feeding that was most notable in gWAT of Casp2−/− mice
(Figures 7c and d). This is opposite to the common
observation of increased p53 following HFD feeding,28,33
and may be attributable to the 6-h fast before tissue harvest
although thiswas not confirmed. At the transcript level, we also
observed higher levels of p53 in gWAT of Casp2−/− mice
compared withWTunder both SLD andHFD conditions, which
corresponded with a significant increase in p21 levels
(Figure 7d). In contrast, we detected decreased p53 levels in
iBAT, in SLD-fed Casp2−/− mice compared with WT controls
(Figure 7c) and were unable to detect p21 transcript in this
tissue. These data indicate that p53 levels in iBAT are not
associated and do not contribute to the observed protection
from diet-induced obesity in Casp2−/− mice.26
Discussion
Caspase-2 has previously been implicated in lipidmetabolism,
glucose homeostasis and ageing.8,9,11 In this study, we show
that altered glucose homeostasis in Casp2−/− mice is the
result of a whole-body shift in fuel choice towards increased
carbohydrate utilisation. We show that caspase-2 is an
intrinsic mediator of basal energy metabolism and provide
further evidence to support a direct role for caspase-2 in
adipocyte biology and fat expansion. In addition, we show that
caspase-2 deficiency protects from the development of HFD-
induced obesity, insulin resistance and NAFLD. A growing
body of evidence now suggests that hyperinsulinemia
precedes the development of insulin resistance34 and as such,
altered insulin levels on HFDmay be part of the mechanism of
caspase-2 function. Similar to findings from Western diet fed
mice,16 protection from obesity likely involves increased
browning of WATand reduced adipocyte cell death. However,
as we have identified an intrinsic difference in fuel utilisation in
the Casp2−/− mice with no difference in adipocyte cell death
under normal dietary conditions, it is unlikely that the apoptotic
function of caspase-2 is a contributing factor to the metabolic
function although this requires further investigation.
Altered substrate utilisation in Casp2−/− mice is identifiable
by the shift in RQ value. Although the change in RQ, although
highly significant, appears to be small it is physiologically
important as it is not because of a short-term change, for
example, a short burst of exercise, but is a more sustained
effect, already present immediately post-weaning of Casp2−/−
mice, which is likely to have long-term physiological outcomes.
In addition, it is well established that RQ values will fall in
adaptation to exposure to a HFD and this magnitude in
humans has been observed to be in the range of 0.03,35 which
is less than the observed difference in the Casp2−/− mice.
Smaller adipocytes are known to be more insulin sensitive
and thus have greater glucose uptake.36 Although altered
glucose homeostasis in Casp2−/− mice appears to be
independent of insulin sensitivity, it is possible that the
whole-body shift towards increased carbohydrate utilisation
inCasp2−/−mice is a direct result of the smaller adipocyte size
and reduced adipose mass. Alternatively, altered metabolic
flux in non-adipose tissues, such as skeletal muscle or liver,
may result in increased energy demand and reliance on
glycolysis. In turn, this may cause an adaptive response in
WATand be driving the phenotype ofCasp2−/−mice. However,
we observed no major differences in key glucose or lipid
metabolism genes in SLD-fed Casp2−/− mice consistent with
our previous findings.8 Interestingly, however, the HFD did
upregulate expression of UCP3 and Cpt1a/b in iBAT and
skeletal muscle in Casp2−/−mice. Although this suggests that
an increase in fatty acid oxidation in these tissues, UCP3 has
been identified as an important regulator of adaptive thermo-
genesis (increased heat production) in both skeletal muscle
and BAT.37 Thus, this could be part of the mechanism
providing protection from HFD-induced obesity and future
studies will need to investigate if heat production is altered in
Casp2−/− mice.
An increase in UCP1 expression in gWAT is indicative of
increased browning of gWAT in HFD-fedCasp2−/−mice and is
similar to findings in Western diet fed Casp2−/− mice.16 As
browning of WAT is mostly due to de novo generation of new
beige/brite adipocytes as opposed to recruitment or conver-
sion of cells,38 the data suggest that hyperplasia may be
increased in HFD-fed Casp2−/− mice as a means to help
mitigate the effects of excess lipid consumption. This is
supported by the maintenance of adiponectin and PPARγ in
Figure 7 Caspase-2 deficiency increases UCP1levels in gWAT following HFD feeding and alters p53 expression. (a and b) Gene expression (relative to SLD-fed WT)
measured relative by qPCR in (a) iBATand (b) gWATof mice fed SLD or HFD for 12 weeks. Heatmaps summarise genes significantly increased or decreased by diet or genotype.
Bar graphs of expression for some selected genes are shown (n= 5–6 per group). (c-f) Immunoblot analysis of p53 and UCP1 protein and gene expression of p53 and p21 in
(c and d) iBATand (e and f) gWATof WTand Casp2−/−mice fed HFD for 12 weeks with bar graphs in c and d displaying densitrometric analysis. β-Actin used as a loading control
for immunoblots. Values are means± S.D. Statistical significance indicated as *Po0.05, **Po0.01, ***Po0.001
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HFD-fed Casp2−/− mice in this study and the observation of
increased proliferation ofCasp2−/− adipose-derivedmesench-
ymal stem cells16 although differentiation potential was not
assessed in that study. A decrease in bone marrow PPARγ in
Casp2−/− suggests that caspase-2 expression may be
involved in adipocyte differentiation.19 However, we observed
no difference in PPARγ gene expression in gWAT of SLD-fed
Casp2−/− mice in this study and previously observed no
difference in PPARγ in aged fed and fasted Casp2−/− livers or
gWAT.8
Caspase-2 deficiency results in increased susceptibility to
oxidative stress-induced damage and a mild-premature
ageing phenotype.11,15 In addition, glucose metabolism is
generally upregulated in response to increase energy
demand. Therefore, we propose that global deletion of
caspase-2 alters metabolic pathways resulting in mild energy
stress. In turn, this increases energy demand resulting in
adaptive remodelling that drives the phenotype of Casp2−/−
mice. This would explain why caspase-2 deficiency results in
favourable glucose homeostasis and protection from HFD-
induced obesity while paradoxically increasing their suscept-
ibility to oxidative stress-induced damage and premature
ageing. Further studies will now be required to determine the
tissue-specific roles of caspase-2 to help elucidate its precise
molecular mechanism.
In conclusion, we have shown that caspase-2 is an intrinsic
mediator of basal energy metabolism. In addition, we provide
further evidence to support a direct role for caspase-2 in
adipocyte biology, fat expansion and its potential as a
therapeutic target from the treatment of obesity and metabolic
disease. Although our findings demonstrate that the mechan-
ism of caspase-2 in metabolism likely involves non-apoptotic
functions, important questions remain as to what the
substrates of caspase-2 are and whether the metabolic
function is fully independent of the function of caspase-2 in
growth arrest and apoptosis of cells carrying mitotic
aberrations.32,39
Materials and Methods
Animal studies. Male WT and Casp2−/− mice on a C57BL/6J background11
were used for experimental studies from 4-week of age. Animal ethics approval for
this research was obtained from the South Australian Health and Medical Research
Institute (SAHMRI) and University of Adelaide Animal Ethics Committees Animal
Ethics Committees, in accordance with National Health and Medical Research
Council of Australia guidelines. Mice were housed in pathogen-free conditions at the
SAHMRI Bioresources Facility (SAHMRI, Adelaide, SA, Australia) under a 12-h
light–dark cycle (lights on at 0600 hours) with constant temperature (20–23 °C) and
ad libitum access to food and water. Mice were fed either SLD (Teklad global 18%
protein rodent, irradiated diet #2918; Harlan, Indianapolis, IN, USA) or HFD (60% kJ
from fat; made in-house as per Research Diets formula for D12492) for 12 weeks
beginning at 5 weeks of age. Mice were killed at the same time of day in the light
phase (1200–1400 hours) after a 6- to 8-h fast in order to stabilise systemic
parameters and to allow the measurement of blood biochemistry in the fasting state.
All animals were anaesthetised with isoflurane, blood collected by cardiac puncture
and killed by cervical dislocation. Blood samples were collected in EDTA tubes for
isolation of plasma. Tissues were collected upon killing, weighed (liver, gWAT and
iBAT), snap-frozen in liquid nitrogen and maintained at − 70 °C until analysed.
Metabolic phenotyping. Metabolic measurements (food intake, locomotor
activity, VO2 consumption and VCO2 production) were obtained using the
Promethion metabolic phenotyping system (Sable Systems, Las Vegas, NV,
USA). Mice were housed in the Promethion system for 48–72 h with ad libitum
access to food and water. Monitoring was performed for 24–48 h after mice
acclimatised to cages for 6–12 h. The RQ was calculated as the ratio of VCO2/VO2
with an RQ= 0.7 indicative of pure fat oxidation and an RQ= 1.0 indicative of pure
carbohydrate oxidation.
Tissue and serum biochemistry. Plasma triglycerides were measured by
automated analysis (CSIRO, Adelaide, SA, Australia). Insulin and leptin plasma
levels were measured using the Rat/Mouse insulin ELISA kit (cat # EZRMI-13 K)
and Mouse Leptin ELISA kit (cat #EXML-82 K; Millipore, Bedford, MA, USA).
Glycogen and FFAs in skeletal muscle and liver tissue were determined using
commercially available assay kits (BioVision, Milpitas, CA, USA; Sigma, St. Louis,
MO, USA).
IPGTT, IPITT and insulin resistance. Glucose and insulin tolerance
testing were performed following intraperitoneal injection of 1 g/kg glucose or 0.5 U/
kg insulin/kg, respectively, after a 6- to 8-h fast as previously described.8 The
HOMA-IR (HOMA-IR= fasting plasma insulin × fasting blood glucose/22.5)
reflecting insulin resistance was calculated from fasting blood glucose and insulin
levels measured after 12 weeks of HFD feeding using iHOMA2 Version 8.82.R2.40
MRI body composition analysis. Whole-body fat and lean mass were
determined via an 3D T1-weighted gradient echo acquired with a benchtop MRI
system (Bruker Icon 1T; Bruker Physik GmbH, Ettlingen, Baden Wuerttemberg,
Germany) in live, 17-week old mice, anaesthetised with isoflurane. ITK snap (www.
itksnap.org) was used for consequent segmentation of the scans.
Real-time qPCR. For standard qPCR, total RNA was extracted from frozen
tissue, reverse transcribed and performed as previous described.9 Gene expression
was normalised to housekeeping gene (β-actin or TATA-binding protein) and then
expressed as fold change of SLD-fed WT mice using the 2-ΔΔCT method. Primer
sequences are provided in Supplementary Table S1.
For RT2 Profiler PCR array (Qiagen/SA Biosciences, Valencia, CA, USA) analysis,
first-strand cDNA was synthesised from total RNA using the RT2 First strand cDNA
synthesis kit (Qiagen). The RT2 Profiler PCR array system was set up, run and
analysed on the Viaa 7 Real-Time PCR System (Thermo Fisher Scientific Inc.,
Wilmington, DE, USA) according to the manufacturer's instructions. RT2 Profiler PCR
arrays used were: mouse fatty liver (#PAMM-157Z); mouse glucose metabolism
(#PAMM-006Z); mouse insulin resistance (#PAMM-156Z, Qiagen/SA Biosciences).
Gene lists and functional grouping are provided in Supplementary Data S1-S3. PCR
arrays were 96 × 4 format allowing for four-independent samples to be run on each
array. Data were processed using RT2 Profiler PCR Array Data Analysis version 3.5
online software (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
Immunoblotting. Proteins were isolated from tissues, resolved by SDS-PAGE
then transferred to PVDF membrane as previously described.8 Membranes were
immunoblotted with the primary antibodies specific to: caspase-3 (clone 8G10,
#9665), cleaved caspase-3 (#9664) and p53 (clone 1C12, #2524; Cell Signalling
Technology, Beverly, MA, USA); UCP1 (#ab10983; Abcam, Cambridge, MA, USA);
and β-actin clone AC-15 (#A5441; Sigma-Aldrich, St. Louis, MO, USA).
Densitrometric analysis was performed using Image J software (NIH, Bethesda,
MD, USA).
Histology and TUNEL. Standard methods were used for haematoxylin/eosin
staining of tissues fixed in HistoChoice (Sigma-Aldrich). TUNEL staining and
quantitation of apoptotic cells was performed as described.13
Statistical analysis. Statistical analysis was performed using GraphPad Prism
software (v 6.0, San Diego, CA, USA). Data are expressed as mean±S.D. or
mean±S.E.M. For pair-wise comparisons a two-tailed unpaired t-test with Welch’s
corrections was used. For multi-group comparisons, one-way or two-way ANOVA
was used with Tukey’s post hoc testing unless stated otherwise. Values of Po0.05
were considered statistically significant
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